FDA Alerts Providers to Safety Risks Associated with Cesium Chloride
The Food and Drug Administration today alerted health care providers to safety risks associated with cesium chloride, a mineral salt sometimes taken by cancer patients who seek alternative treatments. Reported adverse events included QT prolongation (a dangerous abnormality that can impair the heart’s ability to maintain a normal rhythm), low potassium, seizures, potentially lethal arrhythmias, fainting, cardiac arrest and death. FDA also said it intends to move cesium chloride to the category of substances that present significant safety risks in compounding.
Related News Articles
Headline
The Food and Drug Administration has identified a Class I recall of Q’Apel Medical 072 Aspiration System after the company submitted three device event reports…
Headline
The Food and Drug Administration has issued alerts for issues with certain catheters made by BD and Conavi. BD identified an increase in material fatigue…
Headline
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
Headline
As part of the AHA's Patient Safety Initiative, a dedicated webpage features case studies showing how hospitals and health systems across the nation are…
Headline
The Food and Drug Administration has identified a Class I recall of Medtronic Aortic Root Cannulas due to a risk of unexpected loose material in the male luer…
Headline
A study published March 31 by the National Institutes of Health found that adults living in rural areas have worse cardiovascular health than those in urban…